NCT01621477 · OUTCOME

Incidence of Malignant Relapse

T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant · Source last updated 2017-02-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: participants
Interval / dispersion: Not reported
Time frame: One year post transplantation.

What was measured

Estimate the incidence of malignant relapse at one year post-transplant. The number of participants with malignant relapse or progressive disease is given. Relapse was evaluated using standard WHO criteria for each disease.

Groups in this outcome

Treatment

Study participants (excluding donors) who were enrolled and underwent transplant.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treatment	17

Reported measurements

Source class 1

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment	10	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
10

denoms

counts
group Id
OG000
value
17
units
Participants

description

groups

description
Study participants (excluding donors) who were enrolled and underwent transplant.
id
OG000
title
Treatment

param Type

NUMBER

reporting Status

POSTED

time Frame

One year post transplantation.

title

Incidence of Malignant Relapse

type

SECONDARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice